{"id":54193,"date":"2023-02-23T18:06:05","date_gmt":"2023-02-23T17:06:05","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/valbiotis-publishes-its-letter-to-shareholders-and-its-2023-financial-calendar\/"},"modified":"2023-02-23T18:06:05","modified_gmt":"2023-02-23T17:06:05","slug":"valbiotis-publishes-its-letter-to-shareholders-and-its-2023-financial-calendar","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/valbiotis-publishes-its-letter-to-shareholders-and-its-2023-financial-calendar\/","title":{"rendered":"Valbiotis Publishes Its Letter to Shareholders and Its 2023 Financial Calendar"},"content":{"rendered":"<div>\n<p>LA ROCHELLE, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News:\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20230223005567\/en\/1113003\/5\/LOGO-NOIR.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230223005567\/en\/1113003\/21\/LOGO-NOIR.jpg\"><\/a><\/p>\n<p>\nValbiotis (FR0013254851 \u2013 ALVAL, PEA \/ SME eligible), a commercially oriented Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, today publishes its 2023 Letter to Shareholders including its 2023 financial calendar.\n<\/p>\n<p>\nIn this new edition you will find:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nThe message from S\u00e9bastien PELTIER, CEO and co-founder of Valbiotis, to shareholders, who provide invaluable support at a time of strategic acceleration;\n<\/li>\n<li>\nAn overview of the next key milestones: the results of the Phase II\/III REVERSE-IT clinical study on TOTUM\u202263 in prediabetes, the signature of licensing and\/or distribution partnerships with major regional or global nutrition and health players, internationally for TOTUM\u2022070 (LDL cholesterol) and proprietary marketing of TOTUM\u2022070 in France;\n<\/li>\n<li>\nInsights on: the dietary supplement market, TOTUM\u2022070&#8217;s positioning, advances in CSR, the R&amp;D program on micro-algae;\n<\/li>\n<li>\nStock market information on Valbiotis shares.\n<\/li>\n<\/ul>\n<p>\nValbiotis also announces its financial calendar for 2023:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nMarch 15: publication of the 2022 Annual Report;\n<\/li>\n<li>\nMay 2: Annual General Meeting (participation details to be announced);\n<\/li>\n<li>\nSeptember 28: publication of the 2023 Half-Yearly Report.\n<\/li>\n<\/ul>\n<p>\nYou can find all the relevant information, such as financial reports, general meeting documents, stock exchange data, letters to shareholders, the corporate presentation and the universal registration document on the Company&#8217;s website <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.valbiotis.com%2F&amp;esheet=53340936&amp;newsitemid=20230223005567&amp;lan=en-US&amp;anchor=www.valbiotis.com&amp;index=1&amp;md5=a878d89d25dcb563362d0f91e7dffeb5\" rel=\"nofollow noopener\" shape=\"rect\">www.valbiotis.com<\/a>, in the &#8220;Investors&#8221; section (<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.valbiotis.com%2Finvestisseurs&amp;esheet=53340936&amp;newsitemid=20230223005567&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.valbiotis.com%2Finvestisseurs&amp;index=2&amp;md5=9133b2e2803c7ce6711fe78f8dde5a02\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.valbiotis.com\/investisseurs<\/a>).\n<\/p>\n<p>\nDue to environmental considerations, as part of our commitments, our \u201cLetter to Shareholders\u201d will now be offered in digital format only: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.valbiotis.com%2Fwp-content%2Fuploads%2F2023%2F02%2F2023-02-23_LTS-No6.pdf&amp;esheet=53340936&amp;newsitemid=20230223005567&amp;lan=en-US&amp;anchor=Letter+to+Shareholders+No.6&amp;index=3&amp;md5=736cdbec2963dc9a94bda415f4d74ee6\" rel=\"nofollow noopener\" shape=\"rect\">Letter to Shareholders No.6<\/a>.\n<\/p>\n<p>\nAbout Valbiotis\n<\/p>\n<p>\nValbiotis is a commercially oriented Research &amp; Development company, committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases in response to unmet medical needs.<br \/>\n<br \/>Valbiotis has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of health nutrition products designed to reduce the risk of major metabolic diseases, relying on a multi-target strategy enabled by the use of plant-based terrestrial and marine resources.<br \/>\n<br \/>Internationally, its products are intended to be the subject of licensing and\/or distribution agreements with global or regional health and nutrition players. In France, Valbiotis will be responsible for marketing its own products.<br \/>\n<br \/>Created at the beginning of 2014 in La Rochelle, the Company has forged numerous partnerships with leading academic centers. The Company has established three sites in France \u2013 P\u00e9rigny, La Rochelle (17) and Riom (63) \u2013 and a subsidiary in Quebec City (Canada).<br \/>\n<br \/>Valbiotis is a member of the &#8220;BPI Excellence&#8221; network and has been recognized as an &#8220;Innovative Company&#8221; by the BPI label. Valbiotis has also been awarded &#8220;Young Innovative Company&#8221; status and has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). Valbiotis is a PEA-SME eligible company.<br \/>\n<br \/>For more information about Valbiotis, please visit: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.valbiotis.com&amp;esheet=53340936&amp;newsitemid=20230223005567&amp;lan=en-US&amp;anchor=www.valbiotis.com&amp;index=4&amp;md5=7398535ca8ffef6359a5db16ddc19303\" rel=\"nofollow noopener\" shape=\"rect\">www.valbiotis.com<\/a>\n<\/p>\n<p class=\"bwalignr\">\nName: Valbiotis<br \/>\n<br \/>ISIN code: FR0013254851<br \/>\n<br \/>Mnemonic code: ALVAL<br \/>\n<br \/>EnterNext\u00a9 PEA-PME 150\n<\/p>\n<p>\nThis press release contains forward-looking statements about Valbiotis\u2019 objectives. Valbiotis considers that these projections are based on rational hypotheses and the information available to Valbiotis at the present time. However, in no way does this constitute a guarantee of future performance, and these projections may be affected by changes in economic conditions and financial markets, as well as certain risks and uncertainties, including those described in the Valbiotis Universal Registration Document filed to the French Financial Markets Regulator (AMF) on May 19, 2022, and completed by an amendment on November 8, 2022. This document is available on the Company\u2019s website (<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.valbiotis.com%2F&amp;esheet=53340936&amp;newsitemid=20230223005567&amp;lan=en-US&amp;anchor=www.valbiotis.com&amp;index=5&amp;md5=dd9d66a3c1133c85bea984c2b02fb000\" rel=\"nofollow noopener\" shape=\"rect\">www.valbiotis.com<\/a>).<br \/>\n<br \/>This press release and the information it contains do not constitute an offer to sell or subscribe, or a solicitation to purchase or subscribe to Valbiotis\u2019 shares or financial securities in any country.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nCorporate communication \/ Valbiotis<br \/>\n<br \/>Carole Rocher<br \/>\n<br \/>Communication and Public Affairs Director<br \/>\n<br \/>+ 33 6 77 82 56 88\n<\/p>\n<p>\nMarc Delaunay<br \/>\n<br \/>Communication Manager<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#97;&#x69;&#x6c;&#116;&#111;&#x3a;&#x6d;&#101;&#100;&#x69;&#x61;&#64;&#118;&#x61;&#x6c;&#98;&#105;&#x6f;&#x74;&#105;&#115;&#x2e;&#x63;&#111;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">m&#101;&#100;&#x69;&#x61;&#x40;&#x76;a&#108;&#98;&#105;&#x6f;&#x74;&#x69;s&#46;&#99;&#111;&#x6d;<\/a>\n<\/p>\n<p>\nFinancial communication \/ Seitosei Actifin<br \/>\n<br \/>St\u00e9phane Ruiz<br \/>\n<br \/>Associate Director<br \/>\n<br \/>+33 1 56 88 11 14<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;&#105;&#x6c;&#116;&#x6f;&#58;&#x73;&#114;&#x75;&#105;&#x7a;&#64;&#x61;c&#x74;i&#x66;i&#x6e;&#46;&#x66;r\" rel=\"nofollow noopener\" shape=\"rect\">s&#114;&#117;&#x69;&#x7a;&#x40;&#x61;c&#116;&#105;&#102;&#x69;&#x6e;&#x2e;fr<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>LA ROCHELLE, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News: Valbiotis (FR0013254851 \u2013 ALVAL, PEA \/ SME eligible), a commercially oriented Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, today publishes its 2023 Letter to Shareholders including its 2023 financial calendar. In this new edition you will find: The message from S\u00e9bastien &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/valbiotis-publishes-its-letter-to-shareholders-and-its-2023-financial-calendar\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-54193","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Valbiotis Publishes Its Letter to Shareholders and Its 2023 Financial Calendar - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/valbiotis-publishes-its-letter-to-shareholders-and-its-2023-financial-calendar\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Valbiotis Publishes Its Letter to Shareholders and Its 2023 Financial Calendar - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"LA ROCHELLE, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News: Valbiotis (FR0013254851 \u2013 ALVAL, PEA \/ SME eligible), a commercially oriented Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, today publishes its 2023 Letter to Shareholders including its 2023 financial calendar. In this new edition you will find: The message from S\u00e9bastien ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/valbiotis-publishes-its-letter-to-shareholders-and-its-2023-financial-calendar\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-23T17:06:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230223005567\/en\/1113003\/21\/LOGO-NOIR.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/valbiotis-publishes-its-letter-to-shareholders-and-its-2023-financial-calendar\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/valbiotis-publishes-its-letter-to-shareholders-and-its-2023-financial-calendar\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Valbiotis Publishes Its Letter to Shareholders and Its 2023 Financial Calendar\",\"datePublished\":\"2023-02-23T17:06:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/valbiotis-publishes-its-letter-to-shareholders-and-its-2023-financial-calendar\\\/\"},\"wordCount\":640,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/valbiotis-publishes-its-letter-to-shareholders-and-its-2023-financial-calendar\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230223005567\\\/en\\\/1113003\\\/21\\\/LOGO-NOIR.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/valbiotis-publishes-its-letter-to-shareholders-and-its-2023-financial-calendar\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/valbiotis-publishes-its-letter-to-shareholders-and-its-2023-financial-calendar\\\/\",\"name\":\"Valbiotis Publishes Its Letter to Shareholders and Its 2023 Financial Calendar - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/valbiotis-publishes-its-letter-to-shareholders-and-its-2023-financial-calendar\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/valbiotis-publishes-its-letter-to-shareholders-and-its-2023-financial-calendar\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230223005567\\\/en\\\/1113003\\\/21\\\/LOGO-NOIR.jpg\",\"datePublished\":\"2023-02-23T17:06:05+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/valbiotis-publishes-its-letter-to-shareholders-and-its-2023-financial-calendar\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/valbiotis-publishes-its-letter-to-shareholders-and-its-2023-financial-calendar\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/valbiotis-publishes-its-letter-to-shareholders-and-its-2023-financial-calendar\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230223005567\\\/en\\\/1113003\\\/21\\\/LOGO-NOIR.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230223005567\\\/en\\\/1113003\\\/21\\\/LOGO-NOIR.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/valbiotis-publishes-its-letter-to-shareholders-and-its-2023-financial-calendar\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Valbiotis Publishes Its Letter to Shareholders and Its 2023 Financial Calendar\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Valbiotis Publishes Its Letter to Shareholders and Its 2023 Financial Calendar - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/valbiotis-publishes-its-letter-to-shareholders-and-its-2023-financial-calendar\/","og_locale":"en_US","og_type":"article","og_title":"Valbiotis Publishes Its Letter to Shareholders and Its 2023 Financial Calendar - Pharma Trend","og_description":"LA ROCHELLE, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News: Valbiotis (FR0013254851 \u2013 ALVAL, PEA \/ SME eligible), a commercially oriented Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, today publishes its 2023 Letter to Shareholders including its 2023 financial calendar. In this new edition you will find: The message from S\u00e9bastien ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/valbiotis-publishes-its-letter-to-shareholders-and-its-2023-financial-calendar\/","og_site_name":"Pharma Trend","article_published_time":"2023-02-23T17:06:05+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230223005567\/en\/1113003\/21\/LOGO-NOIR.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/valbiotis-publishes-its-letter-to-shareholders-and-its-2023-financial-calendar\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/valbiotis-publishes-its-letter-to-shareholders-and-its-2023-financial-calendar\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Valbiotis Publishes Its Letter to Shareholders and Its 2023 Financial Calendar","datePublished":"2023-02-23T17:06:05+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/valbiotis-publishes-its-letter-to-shareholders-and-its-2023-financial-calendar\/"},"wordCount":640,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/valbiotis-publishes-its-letter-to-shareholders-and-its-2023-financial-calendar\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230223005567\/en\/1113003\/21\/LOGO-NOIR.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/valbiotis-publishes-its-letter-to-shareholders-and-its-2023-financial-calendar\/","url":"https:\/\/pharma-trend.com\/en\/valbiotis-publishes-its-letter-to-shareholders-and-its-2023-financial-calendar\/","name":"Valbiotis Publishes Its Letter to Shareholders and Its 2023 Financial Calendar - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/valbiotis-publishes-its-letter-to-shareholders-and-its-2023-financial-calendar\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/valbiotis-publishes-its-letter-to-shareholders-and-its-2023-financial-calendar\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230223005567\/en\/1113003\/21\/LOGO-NOIR.jpg","datePublished":"2023-02-23T17:06:05+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/valbiotis-publishes-its-letter-to-shareholders-and-its-2023-financial-calendar\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/valbiotis-publishes-its-letter-to-shareholders-and-its-2023-financial-calendar\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/valbiotis-publishes-its-letter-to-shareholders-and-its-2023-financial-calendar\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230223005567\/en\/1113003\/21\/LOGO-NOIR.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230223005567\/en\/1113003\/21\/LOGO-NOIR.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/valbiotis-publishes-its-letter-to-shareholders-and-its-2023-financial-calendar\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Valbiotis Publishes Its Letter to Shareholders and Its 2023 Financial Calendar"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54193","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=54193"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54193\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=54193"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=54193"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=54193"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}